Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideALNYAlnylam Pharmaceuticals
FinDog View：Neutral
LLYLilly (Eli)
FinDog View：Bullish
| Metric | ALNY | LLY |
|---|
| Close | 227.02 | 1,182.62 |
| Market Cap | $31.1B | $1.11T |
| 1M | −8.71% | +6.00% |
| P/E (TTM) | 38.5 | 41.6 |
| Forward P/E | 28.0 | 26.3 |
| P/E 5-Yr Percentile | — | 13 |
| P/S | 6.5 | 13.9 |
| P/B | 23.0 | 32.8 |
| Dividend Yield | — | 0.75% |
| Latest Quarter Revenue | $1.3B | $23.0B |
| Revenue YoY | +66.9% | +47.7% |
| Gross Margin | 76.9% | 85.8% |
| Latest Quarter EPS | 1.21 | 7.94 |
| Avg Post-Earnings Move | ±1.7% | ±3.5% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | — | 1.08% |
| 90-Day Net Insider Buying | −$0.40M | −$16.0M |
ALNY · Revenue, Last 8 Quarters ($B)
LLY · Revenue, Last 8 Quarters ($B)
